catalyst

An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled — primary completion

as of 2026-07-01
Monitor thisAsk about this
at a glance
2026-09-30 · Estimated (est.) — Registry-estimated date, not yet actual.
Synthesized from structured facts only — each point cited above.

Event

What
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled — primary completion
Type
Trial Readout
Date
2026-09-30
Date type
ESTIMATED est.
Phase
Phase 2,PHASE3
Registry-estimated date, not yet actual. This date is directional and must not be read as settled.
relationships
The graph out of here
trial
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
trial